Is Alector, Inc. (ALEC) a Buy, Sell, or Hold?
Alector, Inc.
NASDAQ:ALEC
$1.5 USD
$0.11 (7.91%)
- Volume
- 718.78K
- Average Volume
- 722.22K
- Market Capitalization
- $166.54M
- P/E Ratio
- -1.26
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $3.40
- Year Low
- $1.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.25
| Source | Headline |
|---|---|
|
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks. reuters.com - 2026-07-08 17:20:31 |
|
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.41 per share a year ago. zacks.com - 2026-05-07 20:12:11 |
|
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) globenewswire.com - 2026-05-07 16:05:00 |
|
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2026-05-07 11:00:51 |
|
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in individuals with early Alzheimer's disease (AD) will be discontinued. globenewswire.com - 2026-04-29 16:05:00 |
